Supernus Pharmaceuticals (SUPN) EBITDA (2011 - 2025)

Supernus Pharmaceuticals (SUPN) has 15 years of EBITDA data on file, last reported at -$3.9 million in Q4 2025.

• On a quarterly basis, EBITDA fell 118.39% year-over-year to -$3.9 million in Q4 2025; TTM through Dec 2025 was -$62.3 million, a 176.27% decrease from a year earlier, with the FY2025 full-year figure at -$62.3 million, down 176.27% from the prior year.
• EBITDA for Q4 2025 stood at -$3.9 million, up from -$60.2 million in the prior quarter.
• Over the last five years, EBITDA for SUPN reached as high as $40.8 million in Q3 2024 and fell as low as -$60.2 million in Q3 2025.
• Historically, EBITDA has averaged $7.3 million across 5 years, with a median of $7.1 million in 2021.
• Across the five-year window, EBITDA sank 255.01% in 2023 and surged 2249.1% in 2024, its largest moves.
• Year by year, EBITDA stood at $6.1 million in 2021, then surged by 463.04% to $34.3 million in 2022, then slumped by 102.9% to -$996000.0 in 2023, then jumped by 2249.1% to $21.4 million in 2024, then tumbled by 118.39% to -$3.9 million in 2025.
• Per Business Quant data, the three most recent EBITDA figures were -$3.9 million in Q4 2025, -$60.2 million in Q3 2025, and $12.1 million in Q2 2025.